Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- B. Celli disclaimer
- Studies in COPD (1)
- Studies in COPD (2)
- COPD survival: oxygen
- BODE index and FEV1 as predictors of mortality
- The history of chronic bronchitis and emphysema
- Spirometry and the course of FEV1 progression
- Spirometry and the curse of FEV1 progression
- Mean FEV1 values by age, for NS vs. CS
- Not all COPD decline equally (1)
- Not all COPD decline equally (2)
- ECLIPSE study
- Bronchodilators action
- Bronchodilators action - illustration
- Pharmacological trials
- B. Celli's trials type
- Salmeterol for the treatment of COPD
- Tiotropium study
- Incidences of cardiovascular events - JUPITER trial
- Death from any cause according to study group
- Landmark trials
- The TORCH trial
- TORCH: rate of decline in FEV1
- Rate of exacerbations requiring systemic steroids
- The TORCH trial as a whole
- The UPLIFT trial
- Bronchodilator response distribution in UPLIFT
- UPLIFT: FEV1 versus FVC response
- The UPLIFT trial as a whole
- Mortality in TORCH and UPLIFT
- UPLIFT: pre & post-bronchodilator FEV1 in COPD
- TORCH - rate of decline in FEV1
- Annual decline in post-bronchodilator FEV1
- Salmeterol vs. Tiotropium (POET)
- Important trials
- Tiotropium + (Placebo, Salmeterol, or S/F)
- Tiotropium vs. Tio/Bud/Formoterol (1)
- Tiotropium vs. Tio/Bud/Formoterol (2)
- New medications
- Efficacy and safety of indacaterol (1)
- Efficacy and safety of indacaterol (2)
- Indacaterol versus Tiotropium (1)
- Indacaterol versus Tiotropium (2)
- Indacaterol provides improvement in trough FEV1
- Roflumilast in COPD treated with 2 LABD (1)
- Roflumilast in COPD treated with 2 LABD (2)
- Change from baseline FEV1 15 days
- The future and conclusions
- Recent improvement in survival after hospitalization
- Conclusions
- Concluding remarks
Topics Covered
- Landmark studies in COPD
- Action of Bronchodilators
- Pharmacological trials
- The future of COPD treatments
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Celli, B. (2012, July 31). Long-acting bronchodilators in COPD [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 28, 2024, from https://doi.org/10.69645/KAYC5625.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Bart Celli has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.